AngioDynamics Reports Strong Q3 Sales, Improved YTD Loss, and Favorable Patent Ruling

summarizeSummary

AngioDynamics reported an 8.9% increase in Q3 net sales, driven by 19% growth in its Med Tech segment, and a reduced net loss for the nine-month period, alongside a favorable patent litigation ruling.

check_boxKey Events

• Q3 FY26 Net Sales Growth

  Net sales increased by 8.9% to $78.4 million for the three months ended February 28, 2026, compared to $72.0 million in the prior year period.

• Improved Nine-Month Net Loss

  The company reported a net loss of $25.3 million for the nine months ended February 28, 2026, an improvement from a net loss of $27.9 million in the same period last year.

• Strong Med Tech Segment Performance

  The Med Tech segment, including Auryon, thrombus management, and NanoKnife, saw net sales grow by 19.0% in Q3 and 19.1% for the nine-month period.

• Favorable Patent Litigation Outcome

  The Federal Circuit affirmed the District Court's finding of patent invalidity in the C.R. Bard case on December 15, 2025, in favor of AngioDynamics, meaning no additional contingent payments are due beyond the minimum annual payments.

auto_awesomeAnalysis

AngioDynamics' latest 10-Q filing details a mixed but overall positive financial performance, highlighted by robust growth in its Med Tech segment and a favorable resolution in a significant patent litigation. While the net loss for the third quarter increased, the nine-month year-to-date net loss significantly improved, and operating cash flow showed a strong positive trend. The Federal Circuit's affirmation of patent invalidity in the C.R. Bard case is a material positive development, reducing future contingent payment obligations. Investors should note the continued strategic focus on Med Tech and the improved operational efficiency, alongside the positive legal outcome.